Jubilant Pharmova (BOM:530019) ROCE % : 7.17% (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Jubilant Pharmova ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Jubilant Pharmova's annualized ROCE % for the quarter that ended in Dec. 2023 was 7.17%.

Jubilant Pharmova ROCE % Historical Data

The historical data trend for Jubilant Pharmova's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jubilant Pharmova ROCE % Chart

Jubilant Pharmova Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

ROCE %

Get a 7-Day Free Trial

13.06

12.46

11.75

9.45

2.21

Jubilant Pharmova Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															2.58	-2.15	3.71	6.83	7.17

Jubilant Pharmova ROCE % Calculation

Jubilant Pharmova's annualized ROCE % for the fiscal year that ended in Mar. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	1963.72	/	( ( (99908.67 - 15916.01)	+	(111566.47 - 17724.02) )	/ 2 )
	=	1963.72	/	( (83992.66	+	93842.45)	/ 2 )
	=	1963.72	/	88917.555
	=	2.21 %

Jubilant Pharmova's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	6892	/	( ( (113996 - 17902)	+	(0 - 0) )	/ 1 )
	=	6892	/	( ( 96094	+	0 )	/ 1 )
	=	6892	/	96094
	=	7.17 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Jubilant Pharmova (BOM:530019) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Jubilant Pharmova ROCE % Related Terms

Thank you for viewing the detailed overview of Jubilant Pharmova's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Jubilant Pharmova (BOM:530019) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Jubilant Pharmova Ltd (BOM:530019) » Definitions » ROCE %

Traded in Other Exchanges

JUBLPHARMA:India

Address

1A, Sector 16A, Noida, UP, IND, 201 301

Website

https://www.jubilantpharmova.com

Jubilant Pharmova Ltd is an integrated global pharmaceutical company. The company's segment includes Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research, Development and Manufacturing Organisation and Proprietary Novel Drugs. It generates maximum revenue from the Radiopharma segment. Geographically, it derives a majority of its revenue from Americas and Europe.

Jubilant Pharmova (BOM:530019) Headlines

No Headlines